Varespladib

SKU: orb1306656

Description

Varespladib

Research Area

Metabolism Research

Key Properties

• CAS Number: 172732-68-2
• MW: 380.39
• Purity: >99.99% (May vary between batches)
• Formula: C₂₁H₂₀N₂O₅
• SMILES: CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1
• Target: Phospholipase
• Solubility: DMSO:60 mg/mL (157.73 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  hnsPLA2:7 nM
• In Vivo:
  In the absence of human sPLA2 in BAL cells, LY315920 (0.1 μM-3 μM) effectively suppresses thrombus formation regulated by human sPLA2 in a concentration-dependent manner. Additionally, in a human conjunctival epithelial cell line, LY315920 (10 μM) significantly inhibits the expression of membrane-bound mucin MUC16 induced by all-trans-retinoic acid (RA). LY315920 also markedly inhibits sPLA2 activity across various animal serums, demonstrated by its IC50 values: 8.1 nM in rats, 5.0 nM in rabbits, 3.2 nM in guinea pigs, and 6.2 nM in humans.
  Read more...
• In Vitro:
  In transgenic mice expressing human sPLA2, oral or intravenous administration of LY315920 (0.3-3 mg/kg) effectively inhibits serum sPLA2 activity in a dose-dependent manner.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Phospholipase, Recombinant, secretory, PLA2, sPLA2, Varespladib, human, group, Inhibitor, IIA, hnsPLA2, inhibit, nonpancreatic, LY 315920, LY315920, LY-315920, anti-inflammatory

Compound Identifiers

PubChem CID

155815